View Cover Illustration

Clinical Challenges in Non-Hodgkin Lymphoma: Biologic Strategies for 2008

Summaries of Lectures From a Satellite Symposium Held in Conjunction With the 49th Annual Meeting of the
American Society of Hematology; Atlanta, GA; December 8-11, 2007

1 AMA PRA Category 1 Credit^™

Release date: May 15, 2008
Expiration date: May 15, 2009

Table of Contents


Optimizing the Use of Biologic Therapies in Low-Grade Lymphoma

Can We Further Improve Outcomes in Diffuse Large B-Cell Non-Hodgkin Lymphoma by Altering the Dose and Schedules of Current Regimens?

Biologic Therapy in Chronic Lymphocytic Leukemia: Current Data and Ongoing Studies

Clinical Advances With Novel Anti-CD20 Antibodies in Non-Hodgkin Lymphoma

Current Trends in Antiangiogenic Therapy in Non-Hodgkin Lymphoma

Therapeutic Approaches to Targeting the Apoptotic Pathway in Lymphoma

Emerging Immunotherapeutics Targeting CD30 and CD40 in Non-Hodgkin Lymphoma and Hodgkin Disease

1. Read the following information before entering the educational activity.
2. Study the educational activity.
3. Complete the CME test.
4. Answer the evaluation questions.
5. After successful completion of the CME test and evaluation, you will receive your certificate of credit online.

• Complete the evaluation and CME test by May 15, 2009, to receive your certificate of credit online.
• CME credit will be granted for only 1 form of participation, either online or via the printed publication.

Treatment options for patients with hematologic malignancies, including non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and Hodgkin disease (HD), are rapidly evolving with the availability of several novel targeted agents and optimization of more commonly used agents. Studies in low-grade lymphoma and DLBCL are aimed at optimizing the dose and schedule of biologic agents in order to improve outcomes. Monoclonal antibodies are being evaluated alone and in combination with standard chemotherapy regimens in CLL. Second- and third-generation anti-CD20 antibodies have demonstrated clinical benefit in patients with NHL. Antiangiogenic agents are also being appraised in NHL. New
strategies targeting the apoptotic pathway are being utilized for patients with several hematologic malignancies. Additionally, anti-CD30 and -CD40 monoclonal antibodies are under clinical development for patients with NHL and HD.

The purpose of this activity is to update physicians on current and emerging therapies involving the optimization of current therapeutic regimens and novel targeted agents in hematologic malignancies.

• Discuss therapeutic strategies that optimize the use of biologic agents in the clinical management of low-grade lymphoma
• Discuss alternate strategies that optimize the dose and schedule of current therapeutic regimens to improve clinical outcomes in DLBCL
• Evaluate the efficacy of monoclonal antibodies alone and in combination with chemotherapy in CLL
• Discuss the functional improvements, mechanisms of action, and clinical advancements of second- and third-generation anti-CD20 antibodies in NHL
• Discuss current data associated with antiangiogenic agents in NHL
• Evaluate the efficacy and safety of agents targeting the apoptotic pathway in anticancer therapy
• Appraise the clinical development of anti-CD30 and -CD40 monoclonal antibodies in the treatment of patients with NHL or HD

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

PER Editorial Staff

Other PER Staff
No relevant relationships to disclose

Satellite Faculty

Sandra Horning, MD
Research Funding – Biogen Idec, Genentech, Inc., GlaxoSmithKline, and Millennium Pharmaceuticals, Inc.
Paid Consultant – Astellas Pharma Inc., Exelixis, Inc., Genentech, Inc., and Genmab
Major Stock/Investment Holder – Boston Scientific Corporation, Eli Lilly and Company, Medtronic, Inc., Pharmacyclics, Schering-Plough Corporation, and Varian Medical Systems, Inc.

Andrew Zelenetz, MD, PhD
Research Funding – Amgen, Biogen Idec, Genentech, Inc., and GlaxoSmithKline
Member of Speaker’s Bureau – GlaxoSmithKline.

Ian Flinn, MD, PhD
Research Funding – Biogen Idec, Cephalon, Inc., and Genentech, Inc.
Paid Consultant – Cephalon, Inc. and Protherics

Bertrand Coiffier, MD, PhD
Paid Consultant – Genentech, Inc., Johnson & Johnson, Roche Pharmaceuticals, and sanofi-aventis U.S.
Member of Speaker’s Bureau – Genentech, Inc., Johnson & Johnson, Millennium Pharmaceuticals, Inc., Roche Pharmaceuticals, and sanofi-aventis U.S.

Kristen Ganjoo, MD
Research Funding – Eli Lilly and Company, and Genentech, Inc.
Paid Consultant – Genentech, Inc., and GlaxoSmithKline
Member of Speaker’s Bureau – Genentech, Inc.

Anas Younes, MD
Member of Speaker’s Bureau – Biogen Idec and Genentech, Inc.

Andres Forero, MD
Research Funding – Biogen Idec, Cephalon, Inc., Daiichi Sankyo Company Ltd., Genentech, Inc., and Seattle Genetics, Inc.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the article page. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

An educational grant for this activity was provided by Genentech BioOncology/Biogen Idec.

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

• Microsoft Internet Explorer Downloads (Outside Source)
• Mozilla Firefox Product Page (Outside Source)

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Clinical Challenges in Non-Hodgkin Lymphoma: Biologic Strategies for 2008
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3456
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com